VeriSee AI for screening macular degeneration and diabetic retinopathy
Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening
NA · National Taiwan University Hospital · NCT06843499
This trial will test whether the VeriSee AI software can help doctors screen for age-related macular degeneration in adults 50+ and diabetic retinopathy in diabetic adults 20+.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital (other) |
| Locations | 1 site (Taipei, Taiwan) |
| Trial ID | NCT06843499 on ClinicalTrials.gov |
What this trial studies
The trial will use the VeriSee AI system to analyze color fundus photographs and produce rapid detection results for ophthalmologists to use as diagnostic support. Participants will have fundus images taken in non-retinal ophthalmology clinics and their clinical history recorded for comparison with standard clinical diagnosis. The study will compare the AI-assisted readings to ophthalmologist decisions and measure clinical and cost-effectiveness outcomes. The goal is to determine whether integrating VeriSee improves screening efficiency, diagnostic consistency, and access to care.
Who should consider this trial
Good fit: Ideal candidates are adults aged 50 and older for AMD screening and diabetic patients aged 20 and older for DR screening who can provide informed consent and attend non-retinal ophthalmology clinic visits.
Not a fit: Patients who are already managed by retinal specialists, cannot undergo fundus photography, are under the age limits, or cannot provide informed consent are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, VeriSee could speed up eye disease screening, improve early detection, and expand access to timely care.
How similar studies have performed: Other AI-based fundus image systems have shown promising diagnostic performance for diabetic retinopathy and AMD in multiple validation studies, though real-world clinical-effectiveness data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above. * VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above. Exclusion Criteria: * The patient does not agree to participate in the trial or is unable to provide informed consent.
Where this trial is running
Taipei, Taiwan
- National Taiwan University Hospital — Taipei, Taiwan, Taiwan (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Artificial Intelligence, imaging analysis, disease diagnosis, macular degeneration, diabetic retinopathy